Subtopic Deep Dive
Type I Interferon Signature in SLE
Research Guide
What is Type I Interferon Signature in SLE?
The Type I Interferon Signature in SLE refers to the characteristic upregulation of interferon-stimulated genes (ISGs) in systemic lupus erythematosus patients, driven by plasmacytoid dendritic cells and linked to disease pathogenesis.
This signature involves overexpression of hundreds of ISGs, detectable in blood and tissues of SLE patients (Banchereau and Pascual, 2006, 945 citations). Plasmacytoid dendritic cells accumulate in cutaneous lesions, producing IFN-α upon RNA autoantigen recognition via TLR7 (Farkas et al., 2001, 721 citations; Lau et al., 2005, 795 citations). Over 50 studies confirm its diagnostic and prognostic value, with therapeutic targeting via IFN blockers showing efficacy (Morand et al., 2019, 1206 citations).
Why It Matters
The Type I IFN signature serves as a biomarker for SLE activity and response to therapies like anifrolumab, an anti-IFNAR monoclonal antibody that improved BICLA responses in 47.8% of patients versus 31.5% placebo (Morand et al., 2019). It guides precision medicine, as high IFN signatures predict better outcomes with IFN blockers over standard care (Furie et al., 2016). Hydroxychloroquine inhibits TLR signaling upstream of IFN production, reducing flares in early disease (Schrezenmeier and Dörner, 2020). EULAR guidelines recommend IFN signature assessment for treatment decisions (Fanouriakis et al., 2023).
Key Research Challenges
Heterogeneity of IFN Signature
IFN signature intensity varies across SLE subsets, complicating diagnostics (Banchereau and Pascual, 2006). Genetic factors like IRF5 haplotypes influence expression levels but not uniformly (Graham et al., 2006). trans-eQTLs identified in blood link to SLE risk alleles, yet tissue-specific effects remain unclear (Westra et al., 2013).
Distinguishing Cause from Effect
Upregulated ISGs correlate with flares, but causality versus epiphenomenon is debated (Farkas et al., 2001). Anifrolumab trials show signature neutralization reduces disease activity, supporting pathogenicity (Morand et al., 2019). Viral mimicry via endogenous RNA needs validation in longitudinal cohorts (Lau et al., 2005).
Therapeutic Targeting Specificity
IFNAR blockade with anifrolumab succeeds in high-signature patients but risks infections (Furie et al., 2016). Balancing efficacy against broad IFN inhibition challenges trial design (Morand et al., 2019). Integration into classification criteria requires standardized assays (Aringer et al., 2019).
Essential Papers
Systematic identification of trans eQTLs as putative drivers of known disease associations
Harm-Jan Westra, Marjolein J. Peters, Tōnu Esko et al. · 2013 · Nature Genetics · 1.7K citations
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
Eva Schrezenmeier, Thomas Dörner · 2020 · Nature Reviews Rheumatology · 1.4K citations
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Martin Aringer, Karen H. Costenbader, David Daikh et al. · 2019 · Annals of the Rheumatic Diseases · 1.4K citations
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · 2019 · New England Journal of Medicine · 1.2K citations
Monthly administration of anifrolumab resulted in a higher percentage of patients with a response (as defined by a composite end point) at week 52 than did placebo, in contrast to the findings of a...
Type I Interferon in Systemic Lupus Erythematosus and Other Autoimmune Diseases
Jacques Banchereau, Virginia Pascual · 2006 · Immunity · 945 citations
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
Richard Furie, Munther A. Khamashta, Joan T. Merrill et al. · 2016 · Arthritis & Rheumatology · 827 citations
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate...
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement
Christina M. Lau, Courtney Broughton, Abigail S. Tabor et al. · 2005 · The Journal of Experimental Medicine · 795 citations
Previous studies (Leadbetter, E.A., I.R. Rifkin, A.H. Hohlbaum, B. Beaudette, M.J. Shlomchik, and A. Marshak-Rothstein. 2002. Nature. 416:603–607; Viglianti, G.A., C.M. Lau, T.M. Hanley, B.A. Miko,...
Reading Guide
Foundational Papers
Start with Banchereau and Pascual (2006) for core mechanisms (945 citations), Farkas et al. (2001) for pDC accumulation in lesions (721 citations), and Lau et al. (2005) for TLR7 autoantigen triggers (795 citations) to grasp pathogenesis basics.
Recent Advances
Morand et al. (2019) for anifrolumab phase 3 efficacy (1206 citations), Furie et al. (2016) for phase 2b data (827 citations), and Fanouriakis et al. (2023) EULAR updates integrating IFN blockers.
Core Methods
Microarray/RNA-seq for signature profiling; flow cytometry for pDCs; IFNAR blockade in trials; eQTL mapping for genetic drivers (Westra et al., 2013).
How PapersFlow Helps You Research Type I Interferon Signature in SLE
Discover & Search
PapersFlow's Research Agent uses searchPapers('Type I IFN signature SLE') to retrieve 250M+ OpenAlex papers, including Banchereau and Pascual (2006); citationGraph maps influence from foundational works like Farkas et al. (2001) to trials like Morand et al. (2019); findSimilarPapers expands to IFNAR antagonists; exaSearch uncovers epigenetic regulators.
Analyze & Verify
Analysis Agent employs readPaperContent on Morand et al. (2019) to extract BICLA response rates (47.8% vs 31.5%), verifies claims with CoVe against Furie et al. (2016) for consistency, and runs PythonAnalysis on eQTL data from Westra et al. (2013) for statistical correlation (p<0.05) with SLE loci; GRADE grading scores anifrolumab evidence as high-quality.
Synthesize & Write
Synthesis Agent detects gaps in IFN signature tissue specificity post-Banchereau (2006), flags contradictions between TLR7 models (Lau et al., 2005) and eQTL drivers (Westra et al., 2013); Writing Agent uses latexEditText for signature pathway diagrams, latexSyncCitations for 50+ refs, latexCompile for polished reviews, and exportMermaid for IFNAR blockade flowcharts.
Use Cases
"Plot IFN signature gene expression correlations from SLE eQTL studies"
Research Agent → searchPapers('IFN signature eQTL SLE') → Analysis Agent → readPaperContent(Westra 2013) → runPythonAnalysis(pandas correlation matrix, matplotlib heatmaps) → researcher gets CSV of top trans-eQTLs driving ISGs.
"Draft LaTeX review on anifrolumab trials in high IFN signature SLE"
Synthesis Agent → gap detection(Morand 2019, Furie 2016) → Writing Agent → latexEditText(manuscript draft) → latexSyncCitations(20 refs) → latexCompile(PDF) → researcher gets camera-ready review with BICLA stats table.
"Find code for IFN signature scoring from SLE papers"
Research Agent → searchPapers('IFN signature SLE code') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets validated R/Python scripts for 6-gene IFN score computation.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(100+ IFN SLE papers) → citationGraph → GRADE all → structured report ranking anifrolumab evidence. DeepScan applies 7-step analysis with CoVe checkpoints to verify Lau et al. (2005) TLR7 model against Westra (2013) eQTLs. Theorizer generates hypotheses linking IRF5 haplotypes (Graham 2006) to signature persistence.
Frequently Asked Questions
What defines the Type I IFN signature in SLE?
It is the overexpression of 200+ interferon-stimulated genes in peripheral blood mononuclear cells of SLE patients, first characterized by microarray profiling (Banchereau and Pascual, 2006).
What methods detect the IFN signature?
qPCR for 6-21 gene panels or RNA-seq for full transcriptome; standardized scores predict disease activity (Farkas et al., 2001; Morand et al., 2019).
What are key papers on IFN signature in SLE?
Foundational: Banchereau and Pascual (2006, Immunity, 945 citations) reviews mechanisms; Morand et al. (2019, NEJM, 1206 citations) validates therapeutic targeting with anifrolumab.
What open problems exist in IFN signature research?
Tissue-specific signatures beyond blood, causality in subsets, and optimal IFN blocker patient stratification remain unresolved (Westra et al., 2013; Fanouriakis et al., 2023).
Research Systemic Lupus Erythematosus Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Type I Interferon Signature in SLE with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.